Agios Pharmaceuticals, Inc. (AGIO) Analysts See $-1.60 EPS

April 17, 2018 - By Stephen Andrade

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) LogoInvestors sentiment increased to 1.22 in 2017 Q4. Its up 0.01, from 1.21 in 2017Q3. It is positive, as 19 investors sold Agios Pharmaceuticals, Inc. shares while 48 reduced holdings. 27 funds opened positions while 55 raised stakes. 45.70 million shares or 2.27% more from 44.69 million shares in 2017Q3 were reported.
Sivik Global Healthcare Limited Liability holds 20,019 shares or 0.42% of its portfolio. Bnp Paribas Arbitrage Sa owns 10,078 shares for 0% of their portfolio. Bnp Paribas Asset Management owns 252,160 shares for 0.12% of their portfolio. Partners Ltd Com invested 0.25% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Valley Advisers Inc reported 157 shares stake. Jennison Lc holds 0.01% or 166,255 shares in its portfolio. Sg Americas Limited Com stated it has 3,432 shares. C Worldwide Grp Inc A S accumulated 0% or 3,200 shares. Contravisory Investment Mngmt reported 0% stake. 32,600 were reported by Capital Sarl. Citadel Advsr Ltd Liability Corporation stated it has 91,470 shares or 0% of all its holdings. Whittier Tru Co Of Nevada owns 140 shares. Columbia Wanger Asset reported 760,116 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 2,600 shares. Cubist Systematic Strategies Ltd Liability Com has 100 shares.

Since January 10, 2018, it had 1 insider purchase, and 19 selling transactions for $16.87 million activity. Bowden Christopher sold $157,500 worth of stock. 3,000 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares with value of $228,128 were sold by Biller Scott. Scadden David also bought $16,688 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Friday, March 16. $173,533 worth of stock was sold by Hoerter Steven L. on Thursday, March 22. Shares for $161,250 were sold by Alenson Carman on Friday, January 12. The insider Foster-Cheek Kaye I sold $557,396.

Analysts expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report $-1.60 EPS on May, 3.They anticipate $0.04 EPS change or 2.56 % from last quarter’s $-1.56 EPS. After having $-1.81 EPS previously, Agios Pharmaceuticals, Inc.’s analysts see -11.60 % EPS growth. The stock increased 0.98% or $0.84 during the last trading session, reaching $86.86. About 325,430 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since April 18, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 4 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Agios Pharmaceuticals had 7 analyst reports since November 2, 2017 according to SRatingsIntel. RBC Capital Markets maintained it with “Buy” rating and $88.0 target in Wednesday, February 14 report. The firm has “Buy” rating by Credit Suisse given on Thursday, February 15. The firm has “Buy” rating by RBC Capital Markets given on Wednesday, November 1. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Outperform” rating given on Wednesday, April 11 by Credit Suisse. The firm has “Buy” rating by SunTrust given on Sunday, November 19. Credit Suisse maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Thursday, November 2 with “Outperform” rating. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Overweight” rating by JP Morgan on Thursday, February 15.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.98 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.